Biotek-snakken — Februar 2020
-
af stor betydning for BGBIO. De har godt nok ikke Fast Track i NDAML men har de bedste resultater i NDAML phase II. Netop Abbvie's Venetoclax blev godkendt pga et phase II forsøg men fejler nu i phase III. Spændende om BGBIO melder noget ud om omprioritering af deres registrerings startegi i AML, hvor de indtil videre satser på at bruge deres Fast Track i R/R AML, hvor deres resultater er knap så imponerende.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind